| Trial ID # | NCT02178722 |
| Phase | II |
| Drug Class | Immunotherapy: Immune Cell Stimulators/IDO |
| Drug Name | Epacadostat |
| Alternate Drug Names | IDO1 Inhibitor INCB024360, INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, 3-dioxygenase Inhibitor INCB024360 |
| Drugs in Trial | Epacadostat, Pembrolizumab |
| Eligible Participant | Recurrent or persistent cancer |
| Patients Enrolled | 463 (Phase II: 37 ovarian; median ≥3 prior therapies) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, evaluated per RECIST |
| Biomarkers | Exploratory: PD-L1 protein |
| Efficacy | ORR: 8% (3PR, n=37) Exploratory analysis PD-L1+ patients: |
| Clinically Significant Adverse Events | Serious AE: none |
| Conclusion | Encouraging anti-tumor activity with acceptable safety profile |
| Reference | Spira AI et al. Efficacy/Safety of Epacadostat Plus Pembrolizumab in Triple-Negative Breast Cancer and Ovarian Cancer: Phase 1/2 ECHO-202 Study. J Clin Oncol (2017) 35 (suppl; abstr 1103) |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.